Curated News
By: NewsRamp Editorial Staff
September 16, 2026
GeoVax Develops Bundibugyo Ebola Vaccine Construct Using Rapid Cloning Tech
TLDR
- GeoVax's rapid MVA cloning creates a BDBV vaccine construct, positioning the company in the expanding global race for outbreak countermeasures.
- GeoVax used its proprietary MVA-based rapid-cloning technology to generate a Bundibugyo virus vaccine construct, building on its filovirus portfolio.
- GeoVax's BDBV vaccine construct advances outbreak preparedness, offering hope for protecting vulnerable communities from Bundibugyo virus disease.
- GeoVax developed a new Bundibugyo virus vaccine construct using rapid cloning, while its mpox vaccine remains the priority.
Impact - Why it Matters
This news matters because it highlights a rapid, adaptable vaccine platform that could be crucial in responding to outbreaks of Bundibugyo virus, a severe and often fatal disease with no licensed vaccine. GeoVax's proven experience with other filoviruses, including Zaire Ebola and Marburg, positions it as a key player in global health preparedness. As outbreaks become more frequent, technologies that enable swift vaccine development are essential. Moreover, the company's efforts align with international calls for accelerated BDBV countermeasures, potentially contributing to a coordinated response that could save lives in affected regions and prevent wider spread.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company based in Atlanta, has announced the development of a vaccine construct targeting Bundibugyo virus (BDBV), the cause of an ongoing outbreak in the Democratic Republic of Congo. The construct was generated using GeoVax's proprietary MVA-based rapid-cloning technology, which allows for swift insertion or replacement of vaccine antigens to respond to emerging infectious disease threats. This milestone builds on the company's existing MVA-based filovirus vaccine portfolio, which includes candidates for Zaire Ebola, Sudan Ebola, and Marburg viruses. These earlier programs have shown encouraging efficacy in preclinical models, including nonhuman primate challenge studies, providing a solid scientific foundation for the BDBV work.
"While GEO-MVA remains our primary development focus, the ongoing, expanding BDBV outbreak represents an opportunity to apply capabilities developed through years of MVA and filovirus research," said David Dodd, Chairman and CEO of GeoVax. He noted that the successful generation of the BDBV-specific construct demonstrates the responsiveness of the company's platform and its potential to contribute to outbreak preparedness. The news comes amid growing global attention to BDBV, with the World Health Organization calling for accelerated vaccine development and CEPI announcing up to $16.5 million in funding for another MVA-based BDBV candidate. GeoVax believes its construct and extensive filovirus experience warrant consideration within this expanding effort, and the company is exploring partnerships, including regional manufacturing in Africa.
GeoVax's priority program remains GEO-MVA, a Modified Vaccinia Ankara-based vaccine for mpox and smallpox, which is advancing under an expedited regulatory pathway with a pivotal Phase 3 trial planned for the second half of 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy that has completed a Phase 1/2 trial in advanced head and neck cancer. With a global intellectual property portfolio and a commitment to strategic partnerships, GeoVax continues to address high-consequence infectious diseases and solid tumor cancers. For more information, visit www.geovax.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Develops Bundibugyo Ebola Vaccine Construct Using Rapid Cloning Tech
